Advertisement

The Pharmacokinetics and Pharmacodynamics of Drugs in Elderly Cachectic (Cancer) Patients

  • Dario Cova
  • Vito Lorusso
  • Nicola Silvestris

Abstract

The word cachexia is derived from the Greek words kakòs, meaning ‘bad,’ and hexis, meaning ‘condition’ [1]. From an epidemiological point of view, while patients with haematological malignancies and breast cancer seldom have this syndrome, most other solid tumours are associated with a high frequency of cachexia [2]. Indeed, its prevalence increases from 50% to more than 80% before death, and in more than 20% of patients cachexia is the main cause of death [3].

Keywords

Glomerular Filtration Rate Atrophic Gastritis Vinca Alkaloid Elderly Cancer Patient Cachectic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tisdale MJ (1997) Biology of cachexia. J Natl Cancer Inst 89:1763–1773PubMedCrossRefGoogle Scholar
  2. 2.
    Inui A (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72–91PubMedCrossRefGoogle Scholar
  3. 3.
    Bruera E (1997) Anorexia, cachexia and nutrition. BMJ 315:1219–1222PubMedGoogle Scholar
  4. 4.
    Yancik R (1997) Cancer burden in the aged: an epidemiological and demographic overview. Cancer 80:1273–1283PubMedCrossRefGoogle Scholar
  5. 5.
    Wildiers H, Highley MS, dei Bruijn EA et al (2003) Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 42:1–30CrossRefGoogle Scholar
  6. 6.
    Tisdale MJ (2000) Metabolic abnormalities in cachexia and anorexia. Nutrition 16:1013–1014PubMedCrossRefGoogle Scholar
  7. 7.
    Kotler DP (2000) Cachexia. Ann Intern Med 133:622–634PubMedGoogle Scholar
  8. 8.
    Vestal RE (1997) Aging and pharmacology. Cancer 80:1302–1310PubMedCrossRefGoogle Scholar
  9. 9.
    Skirvin JA, Lichtman SM (2002) Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging 19:25–42PubMedCrossRefGoogle Scholar
  10. 10.
    Raghuram TC, Krishnasvamy K (1981) Tetracycline absorption in malnutrition. Drug Nutr Interact 1:23–29PubMedGoogle Scholar
  11. 11.
    Lichtman SM, Skirvin JA (2000) Pharmacology of antineoplastic agents in older cancer patients. Oncology 14:1743–1763PubMedGoogle Scholar
  12. 12.
    Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14PubMedCrossRefGoogle Scholar
  13. 13.
    Schrijvers D, Highley M, De Bruyn E et al (1999) Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 10:147–153PubMedCrossRefGoogle Scholar
  14. 14.
    Sotaniemi EA, Arranto AJ, Pelkonen O et al (1997) Age and cytochrome P450-Iinked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharm Ther 61:331–339CrossRefGoogle Scholar
  15. 15.
    Corcoran MB (1998) Polypharmacy in the older patient. In: Balducci L, Lyman GH, Ershler WB Comprehensive geriatric oncology. Harwood Academic Publishers, London, pp 525–532Google Scholar
  16. 16.
    John V, Mashru S, Lichtman J (2003) Pharmacological factors influencing anticancer drug selection in the el-derly. Drugs Aging 20:737–759PubMedCrossRefGoogle Scholar
  17. 17.
    Jorquera F, Culebras DM, Gonzalezgallego J (1996) Influence of nutrition on liver oxidative metabolism. Nutrition 12:442–447PubMedCrossRefGoogle Scholar
  18. 18.
    Sadean MR, Glass PS (2003) Pharmacokinetics in the elderly. Best Pract Res Clin Anaesthesiol 17:191–205PubMedCrossRefGoogle Scholar
  19. 19.
    Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21:33–64PubMedCrossRefGoogle Scholar
  20. 20.
    Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14:2590–2611PubMedGoogle Scholar
  21. 21.
    Vuyk J (2003) Pharmacodynamics in the elderly. Best Pract Res Clin Anaesthesiol 17:207–218PubMedCrossRefGoogle Scholar
  22. 22.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRefGoogle Scholar
  23. 23.
    Kinzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21:33–64CrossRefGoogle Scholar
  24. 24.
    Koren G, Beatty K, Seto A et al (1992) The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 26:363–371PubMedGoogle Scholar
  25. 25.
    Balducci L, Extermann M (1997) Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 80:1317–1322PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Dario Cova
    • 1
  • Vito Lorusso
    • 2
  • Nicola Silvestris
    • 3
  1. 1.Onco-Geriatric Unit, Pio Albergo Trivulzio Institute,Milan, Italy and Geropharmacological Pharmacosurveillance Center, Department of PharmacologyUniversity of MilanMilanItaly
  2. 2.Medical Oncology UnitIRCCS Oncology InstituteBariItaly
  3. 3.Medical Oncology UnitGiorgio Porfiri Oncology Center, Hospital of LatinaLatinaItaly

Personalised recommendations